NeuroPhage Pharmaceuticals, a US-based developer of drugs for Alzheimer’s disease, has raised $12.4m in its series B round led by Mérieux Développement, the quasi-corporate venturing unit of France-based holding company Institut Mérieux. Ireland-based drugs group Shire also participated in the round, while its $7m A round angel investors also reinvested in the company treating plaques…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
